IN THE SPECIFICATION

On page 1, delete lines 4-7, and insert the following:

--The present application is a divisional application of Application Serial No. 08/981,392, filed December 22, 1997, national stage of International Application No. PCT/US96/11178 filed June 28, 1996 (published as WO 97/01571 in English), which claims the benefit of provisional Application Serial No. 60/000,589 filed June 28, 1995, each of which is incorporated by reference herein in its entirety.--

On page 10, line 6, delete "(SEQ ID NO:15)" and insert -- (SEQ ID NOS:15-17) --.

On page 10, line 6, delete "(SEQ ID NO:16)" and insert -- (SEQ ID NO:18) --.

On page 10, line 7, delete "(SEQ ID NO:17)" and insert -- (SEQ ID NOS:19-22) --.

On page 10, line 10, delete "(SEQ ID NO:18)" and insert -- (SEQ ID NO:23) --.

On page 10, line 18, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 10, line 20, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 10, line 22, delete "(SEQ ID NO:34)" and insert -- (SEQ ID NOS:27-42) --.

On page 10, line 22, delete "(SEQ ID NO:35)" and insert -- (SEQ ID NOS:43-47) --.

On page 10, line 23, delete "(SEQ ID NO:36)" and insert -- (SEQ ID NOS:48-64) --.

On page 10, line 34, delete "(SEQ ID NO:37)" and insert -- (SEQ ID NO:4) --.

On page 10, line 35, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 10, line 36, delete "(SEQ ID NO:38)" and insert -- (SEQ ID NO:24) --.

On page 11, line 2, delete "(SEQ ID NOS:39-65)" and insert -- (SEQ ID NOS:65-80) --.

On page 13, line 37, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 14, line 2, delete "SEQ ID NO:1, 3, 11, 14 or 33" and insert -- SEQ ID NO:1, 3, 11, 14 or 26 --.

On page 14, line 16, delete "SEQ ID NO:33" and insert -- SEQ ID NO:26 --.

On page 26, line 23, delete "(SEQ ID NOS:2, 10, 16 and 39-65)" and insert -- (SEQ ID NOS:2, 12, 23 and 65-80) --.

On page 29, line 26, after "used" insert the following text:

A3 -- Two conceptually unique approaches are currently available for the production of human monoclonal antibodies - the 'hybridoma' technique, based on the fusion of antibody-producing B lymphocytes with plasmacytoma cells or lymphoblastoid cell lines; and the use of Epstein-Barr virus (EBV) to 'immortalize' antigen-specific human B lymphocytes. --

On page 29, line 28, after "Milstein", insert -- (The cell lines are made by A4 fusion of a mouse myeloma and mouse spleen cells from an immunised donor.) --

On page 29, line 33, before "In an", insert the following text:

A5 -- In this technique, as in the hybridoma procedure, it is important to use the blood lymphocytes of individuals who have previously been immunized with the antigens and have increased numbers of specific antibody-producing cells. The procedure involves two steps: (1) the enrichment of cells with receptors for the given antigen; and (2) 'immortalization' of these cells by EBV infection.--

On page 30, line 21, after "analogs.", insert the following text:

A6 -- As reported by Huse et al., an Fab expression library was constructed from mRNA isolated from a mouse that had been immunized with the antigen NPN. The PCR amplification of messenger RNA isolated from spleen cells or hybridomas with oligonucleotides that incorporate restriction sites into the ends of the amplified product can be used to clone and express heavy and light chain sequences. Thus, the amplified fragments were cloned into a lambda phage vector in a predetermined reading frame for expression. The combinatorial library was constructed in two steps. In the first step, separate heavy and light chain libraries were constructed, and in the second step, these two libraries were used to construct a combinatorial library by crossing them at the EcoRI site. After ligation, only clones that resulted from combination of a right arm of light chain-containing clones and a left arm of heavy chain-containing clones reconstituted a viable phage. After ligation and packaging, 2.5

x 10^7 clones were obtained. This is the combinatorial Fab expression library that was screened to identify clones having affinity for NPN. In an examination of approximately 500 recombinant phage, approximately 60 percent coexpressed light and heavy chain proteins. The light chain, heavy chain and Fab libraries were screened to determine whether they contained recombinant phage that expressed antibody fragments binding NPN.--

On page 37, line 20, delete "SEQ ID NO:2 or 16" and insert

-- SEQ ID NO:2 or 23 --.

On page 68, line 7, delete "(SEQ ID NO:19)" and insert

-- (SEQ ID NO:81) --.

On page 68, line 8, delete "(SEQ ID NO:20)" and insert

-- (SEQ ID NO:82) --.

On page 68, line 9, delete "(SEQ ID NO:21)" and insert

-- (SEQ ID NO:83) --.

On page 68, line 10, delete "(SEQ ID NO:22)" and insert

-- (SEQ ID NO:84) --.

On page 68, line 31, after "...LGV)" insert the phrase

-- (SEQ ID NO:85) --.

On page 75, line 4, delete "(SEQ ID NO:23)" and insert

-- (SEQ ID NO:86) --.

On page 75, line 4, delete "(SEQ ID NO:24)" and insert

-- (SEQ ID NO:94) --.

On page 75, line 9, delete "(SEQ ID NO:25)" and insert

-- (SEQ ID NO:87) --.

On page 75, line 9, delete "(SEQ ID NO:26)" and insert

-- (SEQ ID NO:88) --.

On page 76, line 12, delete "(SEQ ID NO:27)" and insert

-- (SEQ ID NO:89) --.

On page 76, line 13, delete "(SEQ ID NO:28)" and insert

-- (SEQ ID NO:90) --.

On page 76, line 14, delete "(SEQ ID NO:29)" and insert

-- (SEQ ID NO:91) --.

On page 76, line 15, delete "(SEQ ID NO:30)" and insert

-- (SEQ ID NO:92) --.

On page 76, line 17, delete "(SEQ ID NO:31)" and insert -- (SEQ ID NO:93) --.

On page 76, line 17, delete "(SEQ ID NO:32)" and insert -- (SEQ ID NO:25) --.

On page 76, line 27, delete "(SEQ ID NOS:15,16,17)" and insert -- (SEQ ID NOS:15-22) --.

On page 76, line 33, delete "(SEQ ID NO:18)" and insert -- (SEQ ID NO:23) --.

On page 78, line 5, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 78, line 8, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 78, line 11, delete "(SEQ ID NO:34)" and insert -- (SEQ ID NOS:27-42) --.

On page 78, line 12, delete "(SEQ ID NO:35)" and insert -- (SEQ ID NOS:43-47) --.

On page 78, line 13, delete "(SEQ ID NO:36)" and insert -- (SEQ ID NOS:48-64) --.

On page 78, line 21, delete "(SEQ ID NOS:39 through 65.)" and insert -- (SEQ ID NOS:65-80) --.

On page 78, line 32, delete "(SEQ ID NO:37)" and insert -- (SEQ ID NO:4) --.

On page 78, line 34, delete "(SEQ ID NO:33)" and insert -- (SEQ ID NO:26) --.

On page 78, line 36, delete "(SEQ ID NO:38)" and insert -- (SEQ ID NO:24) --.

After the Figures, insert pages 1-51 of the Sequence Listing submitted herewith.

IN THE CLAIMS:

Please amend the claims as follows:

29 (once amended). An antibody which [is capable of binding the Delta protein of claim 1] binds a vertebrate Delta protein, which Delta protein is encoded by a first